Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL)

NCT01649791 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT01649791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01649791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Roswell Park Cancer Institute
Phase
Not applicable
Overall status
Terminated
Start date
January 31, 2010
Completion date
October 31, 2014
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, chronic lymphocytic leukemia, stage 0 chronic lymphocytic leukemia, stage i chronic lymphocytic leukemia, stage ii chronic lymphocytic leukemia